Safety and tolerability of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study).

被引：0
|
作者：
Guida, Annalisa
Maruzzo, Marco
Lai, Eleonora
Bimbatti, Davide
Pierantoni, Francesco
Dionese, Michele
Fornarini, Giuseppe
Zanardi, Elisa
Murianni, Veronica
Caserta, Claudia
Mosillo, Claudia
Calandrella, Maria Letizia
Sirgiovanni, Grazia
Calabro, Fabio
Cerbone, Linda
Caffo, Orazio
Galli, Luca
Bracarda, Sergio
机构：
[1] Azienda Osped Santa Maria, Dept Oncol, Med & Translat Oncol Unit, Terni, Italy
[2] IRCCS, Ist Oncol Veneto IOV, Oncol 1, Padua, Italy
[3] IRCCS, Ist Oncol Veneto IOV, Oncol Unit 1, Padua, Italy
[4] IRCCS, Ist Oncol Veneto IOV, Oncol Unit 1, Dept Oncol, Padua, Italy
[5] IRCCS, Ist Oncol Veneto IOV, Oncol Unit 1, Dept Med Oncol, Padua, Italy
[6] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
[7] IRCCS Osped Policlin San Martino, UO Clin Oncol Med, Genoa, Italy
[8] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy
[9] Azienda Osped Santa Maria, Dept Oncol, Med & Translat Oncol Unit, Terni, IL, Italy
[10] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy
[11] Santa Chiara Hosp, Trento, Italy
[12] Univ Pisana, UO Oncol Med 2, Univ Azienda Osped, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
688
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study)
    Guida, A.
    Maruzzo, M.
    Lai, E.
    Bimbatti, D.
    Pierantoni, F.
    Dionese, M.
    Caserta, C.
    Mosillo, C.
    Calandrella, M. L.
    Macrini, S.
    Fornarini, G.
    Zanardi, E.
    Damassi, A.
    Calabro, F.
    Cerbone, L.
    Astore, S.
    Galli, L.
    Bracarda, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1218 - S1218
  • [2] Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study
    Guida, Annalisa
    Gili, Alessio
    Mosillo, Claudia
    Maruzzo, Marco
    Lai, Eleonora
    Pierantoni, Francesco
    Bimbatti, Davide
    Basso, Umberto
    Fornarini, Giuseppe
    Rebuzzi, Sara Elena
    Calabro, Fabio
    Cerbone, Linda
    Caserta, Claudia
    Sirgiovanni, Grazia
    Serafin, Debora
    Caffo, Orazio
    Scagliarini, Sarah
    Bracarda, Sergio
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [3] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [4] Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis
    Guida, A.
    Matias, M.
    Albiges, L.
    Derosa, L.
    Loriot, Y.
    Massard, C.
    Fizazi, K.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S521 - S521
  • [5] Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): retrospective analysis
    Guida, A.
    Matias, M.
    Albiges, L.
    Derosa, L.
    Loriot, Y.
    Massard, C.
    Fizazi, K.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2015, 26 : 60 - 60
  • [6] Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study.
    Guida, Annalisa
    Gili, Alessio
    Mosillo, Claudia
    Maruzzo, Marco
    Lai, Eleonora
    Pierantoni, Francesco
    Bimbatti, Davide
    Basso, Umberto
    Fornarini, Giuseppe
    Rebuzzi, Sara Elena
    Calabro, Fabio
    Cerbone, Linda
    Sirgiovanni, Grazia
    Mammarella, Alex
    Serafin, Debora
    Caffo, Orazio
    Scagliarini, Sarah
    Bracarda, Sergio
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 511 - 511
  • [7] Renal safety of sunitinib treatment: A prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Rixe, O.
    Meric, J. B.
    Alexandre, J.
    Goldwasser, F.
    Izzedine, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 36 - 36
  • [8] Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma
    Dizman, Nazli
    Austin, Matthew
    Considine, Bryden
    Jessel, Shlomit
    Schoenfeld, David
    Merl, Man Yee
    Hurwitz, Michael
    Sznol, Mario
    Kluger, Harriet
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 221 - 229
  • [9] Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC)
    Haddad, Housam
    Rini, Brian I.
    Jonasch, Eric
    Tannir, Nizar M.
    Dreicer, Robert
    Garcia, Jorge A.
    Wood, Laura S.
    Elson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data
    Melichar, B.
    Poprach, A.
    Kubackova, K.
    Fiala, O.
    Studentova, H.
    Holeckova, P.
    Lakomy, R.
    Hejduk, K.
    Vyzula, R.
    Buechler, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S516 - S516
12345